Precision Molecular Announces Publication of Preclinical Data Detailing Use of PMI06, a PD-L1 Imaging Agent, to Quantify Accessible Target Levels in Solid Tumors to Guide Therapy

The study also demonstrated how accessible target levels can be used to derive insights into pharmacologic activity of antibodies in tumors and elucidate therapeutic response.